Ma Shengyao, Hu Ruixin, Xue Xiaobin, Qu Meihua, Sun Guoping
School of Pharmacy, Qingdao University, Qingdao, Shandong 266071, P.R. China.
Department of Pharmacy, Qingdao Seventh People's Hospital, Qingdao, Shandong 266034, P.R. China.
Oncol Lett. 2025 Jul 3;30(3):424. doi: 10.3892/ol.2025.15170. eCollection 2025 Sep.
The treatment of non-small cell lung cancer (NSCLC) has been notably improved by the use of immune checkpoint inhibitors (ICIs). Although ICIs have been authorized by the United States Food and Drug Administration for the clinical treatment of NSCLC, concerns remain regarding resistance and adverse reactions. Chemotherapy, targeted therapy and other immunotherapies for cancer have the potential to impact cancer immunity, thereby boosting the ability of the body to kill the tumor cells. This provides preliminary evidence for combined therapy, which has been reported to be effective in numerous clinical trials, resulting in the approval of ICIs for use in combination with chemotherapy. Ongoing studies concentrate on novel approaches that can enhance immune responses against tumors through combined strategies. The present review primarily outlines the key mechanisms of combined treatment and the strategies for combining ICIs in NSCLC, demonstrating the viability of combined therapy.
免疫检查点抑制剂（ICI）的应用显著改善了非小细胞肺癌（NSCLC）的治疗。尽管ICI已获美国食品药品监督管理局批准用于NSCLC的临床治疗，但对耐药性和不良反应的担忧依然存在。癌症的化疗、靶向治疗和其他免疫疗法有可能影响癌症免疫，从而增强机体杀死肿瘤细胞的能力。这为联合治疗提供了初步证据，联合治疗在众多临床试验中已被报道有效，从而使得ICI被批准与化疗联合使用。正在进行的研究集中在通过联合策略增强针对肿瘤的免疫反应的新方法上。本综述主要概述了联合治疗的关键机制以及NSCLC中ICI联合治疗的策略，证明了联合治疗的可行性。
